Spyre Therapeutics presents preclinical and clinical data on three IBD antibodies at UEGW 2026

Spyre Therapeutics disclosed preclinical mouse data showing additive efficacy of its three IBD antibodies—SPY001, SPY002 and SPY003—at United European Gastroenterology Week in Barcelona. The same antibodies were also presented in clinical proof‑of‑concept data, and are being evaluated as monotherapies and pairwise combinations in the Phase 2 SKYLINE platform trial. Silvio Danese, chair of the SKYLINE trial steering committee, said the company is eager to see combination results next year.

The company’s progress signals potential differentiation in the IBD market, and upcoming SKYLINE combination readouts next year could affect Spyre’s valuation and investor sentiment.

  • 1Spyre presented data at United European Gastroenterology Week 2026 in Barcelona on Oct. 18 2026.
  • 2The presentations covered three antibodies: SPY001 (anti‑α4β7), SPY002 (anti‑TL1A) and SPY003 (anti‑IL‑23).
  • 3Preclinical mouse studies showed additive efficacy when the antibodies were combined.
  • 4The antibodies are being tested as monotherapies and pairwise combinations in the SKYLINE Phase 2 platform trial.
  • 5Silvio Danese, M.D., Ph.D., served as presenter for the oral session and is chair of the SKYLINE trial steering committee.
  • 6An oral presentation was scheduled for Sunday, Oct. 18, 15:30‑15:40 CEST, and a moderated poster for Monday, Oct. 19, 16:06‑16:12 CEST.

Sources